Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Videos|August 20, 2014
ASCO President Peter P. Yu on Attending AJMC's Patient-Centered Oncology Care Meeting
Peter Paul Yu, MD, FASCO, who this summer became president of the American Society of Clinical Oncology, shared how the group is leading the discussion of what constitutes value in cancer care, as well as the need to engage all stakeholders in this critical topic.
Advertisement
Peter Paul Yu, MD, FASCO, who this summer became president of the American Society of Clinical Oncology, shared how the group is leading the discussion of what constitutes value in cancer care, as well as the need to engage all stakeholders in this critical topic. Dr Yu will offer a keynote address a
Advertisement
Related to this article
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
4
Extension Studies in TPIP Show Promise in PAH, PH-ILD
5